ArticleScience signaling2019

Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer.

Devon R Blake et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.